Opinion

Video

Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Related Content
Exploring the potential role of ctDNA as a biomarker in kidney cancer
February 7th 2025

Exploring the potential role of ctDNA as a biomarker in kidney cancer

Alan Tan, MD
"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.
Neoantigen cancer vaccine shows encouraging activity in ccRCC
Published: February 6th 2025 | Updated: February 6th 2025

Neoantigen cancer vaccine shows encouraging activity in ccRCC

Hannah Clarke
At a median follow-up of 40.2 months post-surgery, no patients had experienced a disease recurrence.
Urologist speaking with a male patient following a diagnosis of cancer. | Credit: Adobe Stock
February 4th 2025

Urologic Cancer Facts and Updates for World Cancer Day 2025

Patrick Campbell
A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.
Certain genetic predispositions may dictate Wilms tumor development
January 31st 2025

Certain genetic predispositions may dictate Wilms tumor development

Hannah Clarke
"What we show in our research is that cancers develop in different ways, depending on what the underlying genetic change is," says Taryn Treger.
Published data show promise of frontline belzutifan/cabozantinib for ccRCC
January 20th 2025

Published data show promise of frontline belzutifan/cabozantinib for ccRCC

Hannah Clarke
At a median follow-up of 24.3 months, the confirmed objective response rate was 70%.
Cellular structures show link with survival outcomes in ccRCC
January 2nd 2025

Cellular structures show link with survival outcomes in ccRCC

Hannah Clarke
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
© 2025 MJH Life Sciences

All rights reserved.